Pyxis Oncology, Inc. (NASDAQ:PYXS) Short Interest Down 16.3% in April

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) was the recipient of a large decline in short interest during the month of April. As of April 30th, there was short interest totalling 1,850,000 shares, a decline of 16.3% from the April 15th total of 2,210,000 shares. Based on an average trading volume of 749,400 shares, the days-to-cover ratio is currently 2.5 days. Currently, 4.0% of the company's shares are sold short.

Pyxis Oncology Price Performance

PYXS traded down $0.05 during midday trading on Monday, reaching $4.29. 278,709 shares of the company's stock traded hands, compared to its average volume of 739,293. The stock has a market capitalization of $252.60 million, a price-to-earnings ratio of -2.37 and a beta of 1.45. Pyxis Oncology has a 52 week low of $1.35 and a 52 week high of $6.85. The firm has a fifty day moving average of $4.88 and a two-hundred day moving average of $3.45.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last announced its quarterly earnings results on Thursday, March 21st. The company reported ($0.33) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.16. Sell-side analysts forecast that Pyxis Oncology will post -0.97 EPS for the current year.

Institutional Investors Weigh In On Pyxis Oncology

A number of large investors have recently modified their holdings of the stock. Commonwealth Equity Services LLC bought a new stake in Pyxis Oncology during the 3rd quarter valued at approximately $26,000. Acadian Asset Management LLC bought a new position in Pyxis Oncology in the third quarter worth $26,000. Schulhoff & Co. Inc. purchased a new position in Pyxis Oncology during the third quarter valued at $44,000. Radcliffe Capital Management L.P. bought a new stake in shares of Pyxis Oncology during the 3rd quarter valued at $106,000. Finally, Decheng Capital Management III Cayman LLC purchased a new stake in shares of Pyxis Oncology in the 3rd quarter worth about $650,000. Institutional investors own 39.09% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on PYXS shares. Jefferies Financial Group reaffirmed a "buy" rating and set a $10.00 target price on shares of Pyxis Oncology in a report on Tuesday, May 7th. Leerink Partnrs reiterated an "outperform" rating on shares of Pyxis Oncology in a report on Tuesday, January 23rd. BTIG Research began coverage on Pyxis Oncology in a report on Friday, February 9th. They set a "buy" rating and a $8.00 target price for the company. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $7.00 price target on shares of Pyxis Oncology in a research note on Friday, March 22nd. Finally, HC Wainwright reissued a "buy" rating and set a $7.00 price objective on shares of Pyxis Oncology in a research note on Wednesday, April 10th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $8.80.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma.